Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listSelegiline hydrochloride

Selegiline hydrochloride

Synonym(s):(R)-(−)-N,α-Dimethyl-N-(2-propynyl)phenethylamine hydrochloride;R-(−)-Deprenyl hydrochloride;R(−)-N-α-Dimethyl-N-2-propynyl-benzeneethanamine hydrochloride;Selegiline hydrochloride

  • CAS NO.:14611-52-0
  • Empirical Formula: C13H18ClN
  • Molecular Weight: 223.74
  • MDL number: MFCD00069299
  • EINECS: 604-508-9
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-08-05 20:55:42
Selegiline hydrochloride Structural

What is Selegiline hydrochloride?

Description

Deprenyl (14611-52-0) is a potent inhibitor of monoamine oxidase B (MAO- B) which has been used for the treatment of Parkinson’s disease.1,2 Displays neuroprotective effects rescuing nigral dopaminergic neurons after systemic MPTP treatment.3 Rescues PC12 cells from trophic withdrawal-induced apoptosis.4 Glyceraldehyde-3-phosphate dehydrogenase has been found to be the putative target responsible for its neuroprotective effects.5

Chemical properties

Crystalline Solid

The Uses of Selegiline hydrochloride

Selegiline hydrochloride is used to alleviate the symptonms of Parkinsons disease

The Uses of Selegiline hydrochloride

antibacterial

The Uses of Selegiline hydrochloride

Antidepressant, Antiparkinsonian

What are the applications of Application

R(?)-Deprenyl hydrochloride is a neuroprotective agent and inhibitor of MAO-B

brand name

Eldepryl (Somerset); Zelapar (Valeant).

Biological Activity

Selective inhibitor of monoamine oxidase B (MAO-B).

Clinical Use

Monoamine-oxidase-B inhibitor:
Treatment of Parkinson’s disease

Veterinary Drugs and Treatments

Selegiline is approved for use in dogs for the treatment of Cushing’s disease and for Canine Cognitive Dysfunction (so-called “old dog dementia”). Its use for Cushing’s disease is somewhat controversial as clinical studies evaluating its efficacy have shown disappointing results. In humans, selegiline’s primary indication is for the adjunctive treatment of Parkinson’s disease.

Drug interactions

Potentially hazardous interactions with other drugs
Analgesics: hyperpyrexia and CNS toxicity reported with pethidine - avoid; avoid with opioid analgesics.
Antidepressants: avoid with citalopram and escitalopram; increased risk of hypertension and CNS excitation with fluvoxamine, sertraline or venlafaxine, do not start selegiline until 1 week after stopping them, avoid for 2 weeks after stopping selegiline; increased risk of hypertension and CNS excitation with paroxetine, do not start selegiline until 2 weeks after stopping paroxetine, avoid for 2 weeks after stopping selegiline avoid concomitant use with other MAOIs and moclobemide (can lead to hypertensive crisis) - allow at least 14 days before starting a MAOI; avoid concomitant use with fluoxetine, allow 5 weeks between stopping fluoxetine and starting selegiline; allow 14 days between stopping selegiline and starting fluoxetine; increased CNS toxicity with tricyclics and vortioxetine.
Oestrogens and progestogens: concentration of selegiline increased - avoid.
Sympathomimetics: concomitant use is not recommended; risk of hypertensive crisis with dopamine.

Metabolism

Extensive first-pass metabolism in the liver to produce at least 5 metabolites, including desmethylselegiline (norselegiline), N-methylamfetamine, and amfetamine. Plasma concentrations of selegiline metabolites are greatly reduced after doses of the oral lyophilisate preparation, the majority of which undergoes absorption through the buccal mucosa.
Selegiline is excreted as metabolites mainly in the urine and about 15% appears in the faeces.

References

Gerlach et al. (1992), The molecular pharmacology of L-deprenyl; Eur. J. Pharmacol., 226 97 Tetrud and Langston (1989), The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease; Science, 245 519 Tatton and Greenwood (1991), Rescue of dying neurons: a new action of deprenyl in MPTP parkinsonism; J. Neurosci Res., 30 666 Tatton et al. (1994), (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis; J. Neurochem, 63 1572 Kargten et al. (1998), Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl; J. Biol. Chem., 273 5821

Properties of Selegiline hydrochloride

Melting point: 141-142°C
alpha  D25 -10.8° (c = 6.48 in water)
storage temp.  2-8°C
solubility  H2O: >10 mg/mL
form  solid
color  white
optical activity [α]25/D 10.8°, c = 6.48 in H2O(lit.)
Water Solubility  Soluble in water at 100mM
Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
CAS DataBase Reference 14611-52-0(CAS DataBase Reference)

Safety information for Selegiline hydrochloride

Signal word Warning
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
GHS Hazard Statements H302:Acute toxicity,oral
H336:Specific target organ toxicity,single exposure; Narcotic effects

Computed Descriptors for Selegiline hydrochloride

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.